We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

CK-MB Assay Used to Diagnose Acute Myocardial Infarction

By LabMedica International staff writers
Posted on 07 Nov 2017
Creatine Kinase (CK) is an enzyme found in high amounts in muscle tissue due to its role in muscle contraction. CK-MB is found mainly in cardiac muscle, where it comprises 15%-40% of the total CK activity, with the remainder being CK-MM.

Trace amounts of CK-MB are found in skeletal muscle (2%-3% of the total CK activity); therefore, patients with skeletal muscle injury will have increases in the absolute concentrations of CK and CK-MB. Furthermore, release of CK-MB only occurs upon death of myocardial cells and it is not released in the setting of ischemia. CK-MB was therefore considered to be the most useful biomarker for detection of myocardial injury before the introduction of high sensitivity Troponin assays.

Image: The Lumipulse G CK-MB immunoassay, an aid in the diagnosis of acute myocardial infarction, being prepared to run on a LUMIPULSE G1200 instrument (Photo courtesy of Fujirebio Europe).
Image: The Lumipulse G CK-MB immunoassay, an aid in the diagnosis of acute myocardial infarction, being prepared to run on a LUMIPULSE G1200 instrument (Photo courtesy of Fujirebio Europe).

Fujirebio Europe (Ghent, Belgium) announced the CE marking of the Lumipulse G CK-MB immunoassay, which can be used as an aid in the diagnosis of Acute Myocardial Infarction (AMI) or as a marker of re-infarction. The launch of this assay now completes the Lumipulse G Cardiac panel which also includes brain natriuretic peptide (BNP), high sensitivity Troponin I and Myoglobin. The assay utilizes proven Chemiluminescent Enzyme Immunoassay (CLEIA) technology with results that are available in up to 35 minutes. The immunoreaction cartridges are used for in vitro diagnostic use with the LUMIPULSE G instruments for the quantitative measurement of the MB iso-enzyme of the creatine kinase (CK-MB) in human serum or plasma.

Christiaan De Wilde, CEO of Fujirebio Europe, said, “We know that robust assay performance is crucial for clinicians facing the difficult and complex diagnosis of AMI. Building on the robust and reliable Lumipulse G platform, our panel of cardiac assays provides high sensitivity, high precision and a wide dynamic range. These are key factors that ensure you get the right result when time is limited. Added to this, our unique single test cartridge concept helps eliminate reagent waste for cardiac markers such as CK-MB and Myoglobin, assays that will tend to be run in lower volumes.”

Related Links:
Fujirebio Europe


New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Rapid Molecular Testing Device
FlashDetect Flash10
New
Silver Member
Quality Control Material
NATtrol Chlamydia trachomatis Positive Control

Latest Immunology News

Blood Test Predicts Immunotherapy Efficacy in Triple-Negative Breast Cancer
07 Nov 2017  |   Immunology

Simple Genetic Testing Could Predict Treatment Success in Multiple Sclerosis Patients
07 Nov 2017  |   Immunology

Novel Gene Signature Predicts Immunotherapy Response in Advanced Kidney Cancers
07 Nov 2017  |   Immunology